NERV (Minerva) יחס שווי שוק לשווי בספרים

Minerva Neurosciences (NERV) is currently losing shareholder confidence and market share due to regulatory failures, yielding to stronger players. The business relies on developing therapies to combat the negative symptoms of schizophrenia, targeting the global mental health segment. This chart of the company's market valuation, where the indicator stands at -0.48, confirms a bet on scientific authority and an innovative drug for the rehabilitation of severely ill patients.

To minimize risks, it is essential for investors to separate market noise from the actual value of assets. This indicator is calculated as the ratio of market capitalization to equity, determining the size of the business's fundamental premium. Analyzing the historical multiple of market value over book value reveals the true vector of the company's overvaluation. For Minerva Neurosciences (NERV), such a premium reflects market expectations regarding FDA approval of roluperidone. The drug's patent protection creates high intrinsic value that is not reflected on the balance sheet.